comparemela.com

Page 5 - கென வாங் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript

Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript

Senior Vice President of Investor Relations Good evening. Welcome to the Vertex First Quarter 2021 Financial Results Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex s CEO and President; Stuart Arbuckle, Chief Commercial and Operations Officer and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today s press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation those regarding Vertex s marketed CF medicines, our pipeline, expectations regarding the closing of the CRISPR transaction, which is subje

Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript

Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Q1 2021 Earnings Call Operator Thank you for standing by and welcome to the Alnylam Pharmaceuticals First Quarter 2021 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder today s program is being recorded. And now I d like to introduce your host for today s program, Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.SPONSORED:

Big Pharma: How much will companies make off their Covid vaccines this year?

Moderna The Moderna vaccine only hit UK shores for distribution today, but it has been a major driver behind the US’ rapid immunisation programme. The drug was first rolled out in America in December, with President Joe Biden’s order for 600m doses almost enough to vaccinate the entire US population. Moderna has said it expects sales of $18.4bn (£13bn) this year far higher than the $11.2bn predicted by analysts. The vast sales will push Moderna into profit for the first time in its 11-year history, and see its reputation cemented among global pharma giants.  So far, Moderna has finalized deals for around 1.08bn doses of the jab, including 17m for the UK, 50m for Japan and 310m for the EU. The firm, which at its last headcount in 2019 employed just 230 staff, charges $30 for the required two shots in the US and $36 in the EU. Barclays analyst Gena Wang forecasts sales could be as high as $19.6bn this year, $12.2bn in 2022, and $11.4bn in 2023, assuming top-up vaccinations a

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.